Results indicated that the BNT162b2 vaccine already elicited a humoral immune response comparable to that observed in a general population of ostensibly healthy healthcare workers [28] after the first vaccine dose in 93.5% (IgG) and 91.5% (IgA) of non-transplanted CF patients, respectively (Table 2). This evidence concerns the gene CD79A and cystic fibrosis.